At AMT Medical, we provide cutting-edge In Vitro Diagnostic (IVD) solutions to our healthcare partners through our portfolio of innovative IVD products.

Strong R&D capabilities driven by our in-house Doctorate Scientists and vast network of research institutional partners in Singapore, propel the rapid expansion of our IVD offerings. We always have our end-users i.e. patients and medical technologists in mind during our process of product invention. This is reflected in our IVD COVID-19 Direct RT-PCR test kits that are intricately designed to be compact, easy to use and bearing high sensitivity and supreme accuracy.

Our sophisticated world class IVD manufacturing infrastructure, consisting of spacious clean rooms that house 6 laminar flow hoods and 3 Biosafety Cabinets (BSC), 13 fridges/freezers, state-of-the-art robotic platforms and the most up-to-date Biomolecular Analytical Systems, has empowered us to achieve high production output and premium quality of our IVD products concurrently.

During this COVID-19 pandemic, we sought to meet the global demand for testing by up-scaling the manufacturing of our RESOLUTE 2.0 Direct RT-PCR COVID-19 diagnostic kit – the industry-first RNA-extraction free COVID-19 test kit. Its ability to entirely abrogate the RNA extraction step comes with the benefits of saving cost and time; and ridding the constraints in worldwide RNA extraction kits shortages which has impeded the ability for high-volume testing. RESOLUTE 2.0’s ready-to-use reagent cocktail allows crude Nasopharyngeal samples to be tested directly without prior pre-treatment, hence enabling a short turnaround time of 94 samples in about 60 minutes. In just 3 months, we have manufactured and delivered the RESOLUTE 2.0 tests kits for 1,000,000 tests to multiple diagnostics laboratories in Singapore, South-East Asia and internationally.

More information on RESOLUTE 2.0 COVID-19 test kit and RAVE (RESOLUTE 2.0’s complementary high throughput robotic system) can be found our Advanced-Covid-Test site.